GCC 1366: Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients
University of Maryland, Baltimore
University of Maryland, Baltimore
Cancer Trials Ireland
Genmab
Novartis
Conjupro Biotherapeutics, Inc.
Eastern Cooperative Oncology Group
Spanish Breast Cancer Research Group
Criterium, Inc.
Sotio Biotech Inc.
University of Chicago
Centre Oscar Lambret
Centre Oscar Lambret
Centre Oscar Lambret
M.D. Anderson Cancer Center
Centre Oscar Lambret
Centre Oscar Lambret
Karolinska University Hospital
Biocon Limited
Allarity Therapeutics
National Cancer Institute (NCI)
Thomas Jefferson University
University of Michigan Rogel Cancer Center
Penn State University
Medical University of South Carolina
Ramsay Générale de Santé
OHSU Knight Cancer Institute
Genmab
Mayo Clinic
Sanofi
Dana-Farber Cancer Institute
Baylor College of Medicine
M.D. Anderson Cancer Center
Stanford University
University of Virginia
AHS Cancer Control Alberta
University of Texas Southwestern Medical Center
Baylor Research Institute
The Methodist Hospital Research Institute
Mayo Clinic
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Takeda
Ocellaris Pharma, Inc.
Palleos Healthcare GmbH
Seagen Inc.
Fusion Pharmaceuticals Inc.
Fundacio Clinic Barcelona
Institut de cancérologie Strasbourg Europe
Institut de cancérologie Strasbourg Europe
PharmAbcine